Quick Read – The absence of insider selling at Pfizer (PFE) after a sizable one-year rally is a data point retail investors should be weighing. – The signal reflects the steady hand of professionals who see the income and the pipeline as worth waiting on. – The analyst who…
lled NVIDIA in 2010 just named his top 10 stocks and Pfizer wasn’t one of them. Get them here FREE
The smart money on Pfizer (NYSE: PFE) is sending a quieter signal than the financial press typically rewards: institutional analysts are constructive, insiders are not transacting in size in either direction, and the dividend yield is doing the heavy lifting. With shares at $26.21 and a Wall Street consensus target of $29.19, the absence of insider selling into an 11.0% one-year rally is the data point retail investors should weigh. What the Sell Side Actually Says Coverage on Pfizer is broad and divided, leaning toward cautious optimism.
On average, analysts recommend holding shares, and they have a $29.19 consensus price target. Recent actions paint the same picture: UBS held at $27 target, pending the Sigvotatug Phase III readout in mid-2026. Bank of America raised its target to $27 after the Q1 beat, and Citi reiterated its Hold rating at $27.